金吾财讯 | 和铂医药-B(02142)发布公告，公布其首款利用Hu-mAtrIx™人工智能平台开发的下一代靶向ACVR2A/2B单克隆抗体药物LET003的临床前研究数据。结果显示，LET003具有优于多个竞品分子的药代动力学特征；与司美格鲁肽联合用药时，可显着增强减脂效果并有效保护瘦体重。此外，在较低剂量下，LET003即可达到与较高剂量bimagrumab相当的促进瘦体重增加的作用，显示出其在肥胖症治疗中成为同类最佳(Best-in-Class)药物的潜力。据悉，LET003是一款潜在同类最佳的下一代单克隆抗体，靶向激活素受体ACVR2A/2B。ACVR2A和ACVR2B在调控肌肉－脂肪代谢稳态中发挥关键作用。大量临床前及临床研究已证实，将该受体的阻断抗体与GLP-1类减重药物联合使用，可进一步降低体脂，并有效缓解瘦体重流失。LET003是首款依托HumAtrIx™人工智能平台研发的ACVR2A/2B双靶点阻断抗体，具有优于多款竞品的药代动力学特性；在临床前动物模型中，其与GLP-1类药物联用也展现出优异的减脂与保肌增效作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.